Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) and AAV-U7 rescues the severe DMD phenotype in mice

Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) and AAV-U7 rescues the severe DMD phenotype in mice

Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disease caused by an absence of the dystrophin protein, which is essential for muscle fiber integrity. Among the developed therapeutic strategies for DMD, exon skipping approach corrects the frame shift and partially restores dystrophi...

Полное описание

Библиографические подробности
Главные авторы:	Forand, A, Muchir, A, Mougenot, N, Sevoz-Couche, C, Peccate, C, Le Maitre, M, Izabelle, C, Wood, MJA, Lorain, S, Piétri-Rouxel, F
Формат:	Journal article
Язык:	English
Опубликовано:	Elsevier 2020

Схожие документы

Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers
по: Li, Chengxi, и др.
Опубликовано: (2021)

MOTS‐c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice
по: Ning Ran, и др.
Опубликовано: (2020-12-01)

Phosphorodiamidate Morpholino Oligomers-Loaded Nanobubbles for Ultrasound-Mediated Delivery to the Myocardium in Muscular Dystrophy
по: Yoko Endo-Takahashi, и др.
Опубликовано: (2025-02-01)

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study
по: Cirak, S, и др.
Опубликовано: (2011)

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
по: Cirak, S, и др.
Опубликовано: (2011)

AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy
по: Le Hir, M, и др.
Опубликовано: (2013)

Endo-Porter–mediated delivery of phosphorodiamidate morpholino oligos (PMOs) in erythrocyte suspension cultures from Cope's gray treefrog Hyla chrysoscelis
по: Venkateshwar Mutyam, и др.
Опубликовано: (2011-05-01)

PPMO's as therapeutic modulators for myotonic dystrophy type 1
по: Holland, A, и др.
Опубликовано: (2018)

Rescu of severely affected dystrophin/utrophin deficient mice by morpholino-oligomer mediated exon skipping
по: Goyenvalle, A, и др.
Опубликовано: (2010)

Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
по: Goyenvalle, A, и др.
Опубликовано: (2010)

Dystrophin Threshold Level Necessary for Normalization of Neuronal Nitric Oxide Synthase, Inducible Nitric Oxide Synthase, and Ryanodine Receptor-Calcium Release Channel Type 1 Nitrosylation in Golden Retriever Muscular Dystrophy Dystrophinopathy
по: Gentil, C, и др.
Опубликовано: (2016)

Guidelines for morpholino use in zebrafish
по: Stainier, Didier Y. R., и др.
Опубликовано: (2018)

Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model
по: Juri Hasegawa, и др.
Опубликовано: (2024-09-01)

Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA
по: Alexandra Sakai, и др.
Опубликовано: (2024-12-01)

Corrosion studies of Inconel 617 in high temperature air and He-ppmO2 atmospheres
по: Haoxiang Li, и др.
Опубликовано: (2025-01-01)

Lessons learned from vivo-morpholinos: How to avoid vivo-morpholino toxicity
по: David P. Ferguson, и др.
Опубликовано: (2014-05-01)

DMD and West syndrome
по: Cardas, R, и др.
Опубликовано: (2017)

Context dependent effects of chimeric peptide morpholino conjugates contribute to dystrophin exon-skipping efficiency
по: Yin, HF, и др.
Опубликовано: (2016)

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
по: Kinali, M, и др.
Опубликовано: (2009)

Vivo-Morpholinos: A non-peptide transporter delivers Morpholinos into a wide array of mouse tissues
по: Paul A. Morcos, и др.
Опубликовано: (2008-12-01)

Higher baseline heart rate variability in CCHS patients with progestin-associated recovery of hypercapnic ventilatory response
по: Caroline Sevoz-Couche, и др.
Опубликовано: (2024-02-01)

Analysis of DMD translocations
по: Cockburn, D, и др.
Опубликовано: (1991)

Comparative phosphoproteomics of zebrafish Fyn/Yes morpholino knockdown embryos.
по: Lemeer, S, и др.
Опубликовано: (2008)

Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.
по: Koenig, M, и др.
Опубликовано: (1987)

P740: DMD or not DMD? Clinical genome sequencing in the interpretation of complex copy number gains
по: Edward Higginbotham, и др.
Опубликовано: (2024-01-01)

Peptide nucleic acids, morpholinos and related antisense biomolecules /
по: 204120 Janson, Christopher G., и др.
Опубликовано: (2006)

Guidelines for Corticosteroid use in Treatment of DMD
по: Vamshi K. Rao
Опубликовано: (2016-07-01)

The use of Endo-Porter to deliver morpholinos in kidney organ culture
по: George N. Nikopoulos, и др.
Опубликовано: (2008-04-01)

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD
по: Pichavant, C, и др.
Опубликовано: (2011)

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.
по: Pichavant, C, и др.
Опубликовано: (2011)

Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD
по: Godfrey, C, и др.
Опубликовано: (2012)

Affinity Purification of RNA: Sequence-Specific Capture by Nonionic Morpholino Probes
по: J.M. Wages, и др.
Опубликовано: (1997-12-01)

Comprehensive RNA-sequencing analysis in serum and muscle reveals novel small RNA signatures with biomarker potential for DMD
по: Coenen-Stass, AML, и др.
Опубликовано: (2018)

A dinucleotide repeat polymorphism at the DMD locus.
по: Powell, J, и др.
Опубликовано: (1991)

Muscular dystrophy associated with the DMD gene in women
по: E. O. Vorontsova, и др.
Опубликовано: (2024-09-01)

Bessel_DMD: the numerical code based on the scalar Fresnel–Kirchhoff integration to calculate the diffraction and bessel-like beam by using the DMD
по: Pei, Ting-Han, и др.
Опубликовано: (2024)

Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice.
по: Rafael, J, и др.
Опубликовано: (2000)

A female patient carrying a novel DMD mutation with non-random X-chromosome inactivation from a DMD family
по: Ming-Xia Sun, и др.
Опубликовано: (2024-02-01)

Delaying Gal4-driven gene expression in the zebrafish with morpholinos and Gal80.
по: Adèle Faucherre, и др.
Опубликовано: (2011-01-01)

Second-generation compound for the modulation of utrophin in the therapy of DMD
по: Guiraud, S, и др.
Опубликовано: (2015)